Intellia Therapeutics Stock (NASDAQ: NTLA)

Dernières nouvelles pour Intellia Therapeutics (NASDAQ:NTLA) Stock

Intellia Therapeutics

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics Inc

Shares of Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) rose sharply in today's pre-market trading after the company reported better-than-expected third-quarter financial results and issued guidance <a href="https://www.benzinga.com/news/earnings/24/11/41730179/palantir-q3-earnings-revenue-beat-eps-beat-customers-up-39-raises-guidance-results-driven-by-unrele">above consensus estimates</a>.
Revenue increased 5% year over year to $3.07 billion, beating the consensus of $3.05 billion. Adjusted EPS of 77 cents surpassed the street view of 68 cents.
Palantir Technologies shares rose 12.9% to $46.75 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Simpple Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPPL#NASDAQ">SPPL</a>) gained 69.5% to $2.00 in pre-market trading after jumping around 269% on Monday.</li>
<li>Bionomics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) rose 67.6% to $0.3219 in pre-market trading. Bionomics received milestone payment of AUS$1 million from Carina Biotech for BNC101 partnered legacy oncology program.</li>
<li>Avalon GloboCare Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALBT#NASDAQ">ALBT</a>) shares surged 42.4% to $3.19 in pre-market trading after dipping 24% on Monday.</li>
<li>QuinStreet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNST#NASDAQ">QNST</a>) climbed 29.8% to $26.22 in pre-market trading after the company posted upbeat quarterly results and raised its FY25 sales outlook.</li>
<li>Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) gained 26.1% to $87.83 in pre-market trading after the company announced better-than-expected quarterly results.</li>
<li>Zyversa Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares rose 15.3% to $2.10 in pre-market trading after falling 5% on Monday.</li>
<li>Vimeo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMEO#NASDAQ">VMEO</a>) gained 15.2% to $5.54 in pre-market trading after the company posted upbeat quarterly results.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) gained 12.6% to $3.12 in pre-market trading.</li>
<li>Alarum Technologies Ltd &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) gained 16.6% to $14.39 in pre-market trading.</li>
<li>Elevai Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) gained 11.9% to $0.0225 in pre-market trading after the company announced update and extension of pending offer to exchange.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Marqeta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) shares tumbled 38.8% to $3.64 in pre-market trading following weak quarterly sales.</li>
<li>Verrica Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) shares fell 31.4% to $0.98 in pre-market trading after the company posted downbeat quarterly results.</li>
<li>Trio Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPET#NYSE">TPET</a>) dipped 24.8% to $0.0960 in pre-market trading after the company announced a 1-for-20 reverse stock split.</li>
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) shares fell 19.4% to $2.10 in pre-market trading after the company reported weak third-quarter sales.</li>
<li>Lattice Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) declined 18% to $42.55 in pre-market trading following soft fourth-quarter guidance.</li>
<li>Nft Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MI#NYSE">MI</a>) shares dipped 16.1% to $7.50 in pre-market trading after gaining 9% on Monday.</li>
<li>Vast Renewables Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) fell 16.2% to $5.66 in pre-market trading after surging more than 40% on Monday.</li>
<li>Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) fell 15.8% to $103.89 in today's pre-market trading after the company reported worse-than-expected third-quarter financial results and announced it intends to temporarily reduce its quarterly dividend.</li>
<li>Altice USA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATUS#NYSE">ATUS</a>) fell 14.3% to $2.22 in pre-market trading after the company reported weak third-quarter financial results.</li>
<li>Tactile Systems Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) fell 10.3% to $13.55 in pre-market trading after the company posted weak quarterly sales and lowered FY24 sales forecast.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41735761/dow-tumbles-250-points-as-investors-brace-for-high-stakes-presidential-election-greed-index-enters-">Dow Tumbles 250 Points As Investors Brace For High-Stakes Presidential Election: Greed Index Enters &#8216;Fear&#8217; Zone</a></li>
</ul>

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ALAB

ALAR

ALBT

ATUS

BNOX

ELAB

LSCC

NVTS

PLTR

QNST

SPPL

TCMD

TPET

VMEO

VRCA

VSTE

ZVSA

Why Palantir Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

Earnings

SBSW

Sibanye Stillwater Q3 Adjusted EBITDA $184M, Up 9% Year-On-Year

Legal

NFLX

Reuters Reported France's PNF Financial Prosecutor Body Has Carried Out Searches Today At Netflix France, Amsterdam Offices, Citing Judicial Source

Phunware Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) experienced a significant surge in its stock price, climbing 10.27% during pre-market trading on Tuesday, as per <a href="https://pro.benzinga.com">Benzinga Pro</a>. 
What Happened: The stock&#8217;s rise occurred just one day before the U.S. Elections. This increase comes as the company remains linked to former President Donald Trump, having managed his 2020 reelection campaign&#8217;s mobile app.
On Friday, Phunware also revealed that Troy Reisner, the<a href="https://www.benzinga.com/markets/equities/24/11/41712003/trump-linked-phunwares-leadership-shuffle-continues-cfo-joins-ceo-in-exit-queue"> Chief Financial Officer</a>, intends to resign between Nov. 15 and Nov. 30. The company emphasized that Reisner&#8217;s departure is not due to any disagreements over business operations or financial practices. A search for a new CFO is underway. Post the announcement, on Monday, PHUN dropped by 10% during pre-market.
During this transition, Interim CEO Stephen Chen will collaborate with Brendhan Botkin, Vice President of Accounting and Financial Reporting, to oversee the roles of principal financial officer and principal accounting officer. Last month, Phunware announced the<a href="https://www.benzinga.com/news/24/10/41521091/trump-linked-phunware-stock-falls-as-ceo-exits-what-you-need-to-know"> resignation of CEO</a> Michael Snavely, with Stephen Chen assuming the role of interim CEO.
See Also: <a href="https://www.benzinga.com/markets/equities/24/11/41734592/palantir-trump-media-hims-hers-health-nxp-semiconductors-and-tesla-why-these-5-stocks-are-on-inv?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">PLTR, DJT, HIMS, NXPI, TSLA: Top 5 Trending Stocks Today</a>
Why It Matters: Phunware&#8217;s stock has been subject to fluctuations, often influenced by its ties to Trump-related ventures. On Oct. 15, Phunware&#8217;s shares surged amid market momentum and its association with <a href="https://www.benzinga.com/news/24/10/41339350/phunware-stock-skyrockets-amid-trump-association-and-market-momentum-whats-going-on">Trump Media &amp; Technology Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>), which launched its Truth+ streaming service. The platform is set to expand with an iOS app and availability on platforms like Apple TV and Amazon Fire.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41734897/elon-musks-doge-department-mention-gives-dogecoin-boost-to-top-of-daily-gainers-memecoin-s?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s &#8216;DOGE&#8217; Department Mention Gives Dogecoin Boost To Top Of Daily Gainers: Memecoin Spikes 6%</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Equities

General

PHUN

Trump-Linked Phunware Stock Is Surging 10% In Pre-Market: What's Going On?

Guidance

Health Care

Fresenius Medical Care Also Reconfirms Its Targets To Achieve An Operating Income Margin Of 10%-14% By 2025

Fresenius Medical Care Confirms Its Outlook For Fiscal 2024 And Expects Revenue To Grow By A Low- To Mid-single Digit Percent Rate, With Operating Income To Grow By 16%-18% Versus Prior Guidance Of Growth By A Mid- To High-teens Percent Rate

Fresenius Medical Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.35 by 108.57 percent. This is a 28.07 percent increase over earnings of $0.57 per share from the same period last year. The company reported quarterly sales of $4.76 billion which missed the analyst consensus estimate of $4.89 billion by 2.67 percent. This is a 3.57 percent decrease over sales of $4.94 billion the same period last year.

Fresenius Medical Care Q3 2024 Adj EPS €0.73 May Not Be Comparable To €0.35 Estimate, Sales €4.76B Miss €4.89B Estimate

Alex Karp, CEO of Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) has cautioned that Europe could face ruin if it does not adopt <a href="https://www.benzinga.com/topic/artificial-intelligence">artificial intelligence (AI) innovation</a>.
What Happened: &#8220;As America once again forges ahead, our allies and partners in Europe are being left behind,&#8221; Karp stated in a letter to shareholders on Monday.
His warning came as <a href="https://www.benzinga.com/news/earnings/24/11/41730179/palantir-q3-earnings-revenue-beat-eps-beat-customers-up-39-raises-guidance-results-driven-by-unrele">Palantir&#8217;s business growth accelerates</a>, surpassing expectations due to the robust demand for advanced AI technologies from&nbsp;U.S. government and commercial customers.
The company&#8217;s revenue in the&nbsp;last quarter reached a record&nbsp;$726 million,&nbsp;a 30% increase from the&nbsp;same period last year.
Palantir&#8217;s year-over-year revenue growth rate&nbsp;has increased over the past&nbsp;six quarters, rising from 13%&nbsp;in the second quarter of 2023 to 30% in the third quarter of 2024.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/10/41663190/openai-rolls-out-chatgpt-search-google-shares-slide?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">OpenAI Rolls Out ChatGPT Search, Google Shares Slide</a>
In his letter, Karp attributed this growth to&nbsp;early and decades-long investment in&nbsp;technical infrastructure, which is now making large language models valuable to large enterprises.
Palantir has also joined the S&amp;P 500, a goal many thought was fanciful. The company&#8217;s entry into the index was&nbsp;made possible by the strength&nbsp;of its&nbsp;business and expanding demand for&nbsp;its software, he stated.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Karp&#8217;s warning to Europe comes in the wake of Palantir&#8217;s record-breaking Q3 2024 results, which were driven by an &#8220;unrelenting AI demand that won&#8217;t slow down.&#8221;
The U.S. market remains the&nbsp;core of Palantir&#8217;s business, where institutions have responded&nbsp;most rapidly to the promise&nbsp;of AI.
The release of Palantir&#8217;s&nbsp;newest platform, AIP, has transformed&nbsp;the business, with U.S. revenue reaching $499 million in the third quarter, a 44% increase&nbsp;compared to the same period&nbsp;a year earlier.
Wedbush analyst Dan Ives referred to Palantir as the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41732827/messi-of-ai-wall-street-analyst-gushes-over-robust-earnings-from-palantir">&#8220;Messi of AI&#8221; following the company&#8217;s</a> robust earnings. The company&#8217;s customer count grew 39%, and it raised its full-year outlook across all metrics.
Palantir&#8217;s AI gamble has also paid off, with one customer <a href="https://www.benzinga.com/markets/equities/24/11/41734875/palantirs-ai-gamble-pays-off-as-customer-revenue-from-single-customer-jumps-12x-in-under-8-month">increasing its annual recurring revenue twelvefold</a> in less than eight months after implementing the company's AI platform.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41702294/apple-begins-shifting-iphone-17-production-in-india-cooks-china-optimism-and-more-this-week-in-apple?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple Begins Shifting iPhone 17 Production In India, Cook&#8217;s China Optimism, And More: This Week In Appleverse</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Global

Tech

Palantir CEO Alex Karp Warns Europe Risks Doom Without AI

Outlook
In the Stimulation Services segment, the Company anticipates pricing and activity to decline in the fourth quarter. Due to our integrated model and prudent cost management, we are able to navigate cyclicality without sacrificing service and asset quality. Based on ongoing dialogue with operators we anticipate a recovery in activity in 2025 as compared to the fourth quarter of 2024, and we continue to field new inbound requests for additional integrated fleet deployments with the highest demand for electric and Tier 4 dual fuel or DGB technologies. Today, approximately 72% of our active fleets include e-fleet or natural gas-capable equipment.
The Proppant Production segment started to see incremental improvement as we moved through the third quarter, although natural gas-directed activity was subdued and West Texas remains highly competitive. We anticipate that pricing and volumes in the fourth quarter will be impacted by weaker demand. We continue to actively manage operating costs to partially mitigate the impact of lower profitability. We expect a recovery in activity in 2025 relative to the fourth quarter, with a more pronounced potential improvement in oil-levered regions.

ACDC

ProFrac Anticipates Decline In Stimulation Services And Proppant Production Segments In Q4 2024, With Recovery Expected in 2025

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk said on Monday that the company is not considering building a phone, refuting rumors.
What Happened: &#8220;No, we are not doing a phone,&#8221; Musk <a href="https://www.youtube.com/watch?v=7qZl_5xHoBw">said</a> in a podcast with Joe Rogan published on Monday. However, it is not because the company can&#8217;t do it, the CEO said. 
&#8220;We could do a phone since like the operating system in Tesla &#8211; it&#8217;s Linux-based &#8211; but we have written a massive amount of software on top of that. So probably Tesla is in a better position to create a new phone that&#8217;s not Android or iPhone than maybe any company in the world but it is not something we want to do unless we have to,&#8221; Musk said.
The company will have to make a phone if Apple or Google start censoring apps or acting like &#8220;gatekeepers,&#8221; the CEO added.
Tesla currently has its &#8220;plate full&#8221; with its efforts into electric vehicles, enabling autonomous driving, and robotics, Musk said while adding that making a phone would be &#8220;a huge pain the ass.&#8221;
Why It Matters: Musk first hinted at making a phone in November 2022, following his acquisition of Twitter, now rebranded as&nbsp;X, amidst uncertainty about the microblogging platform&#8217;s&nbsp;status on mainstream app stores.
Musk in June gave mixed signals about the company&#8217;s plans to make a phone. One day he announced in a live stream on X that Tesla was not going to make a phone.
Two days later, the CEO said that his tech company X manufacturing a phone running on a custom open-source operating system in partnership with another smartphone maker is "<a href="https://www.benzinga.com/news/24/06/39265691/a-day-after-shutting-down-tesla-phone-rumors-elon-musk-says-it-is-not-out-of-the-question" target="_blank" rel="noreferrer noopener">not out of the question</a>."
Musk <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39306037/tesla-bull-adam-jonas-thinks-tesla-will-make-a-phone-elon-musk-hopes-it-wont-be-nee">later clarified</a> that Tesla could make a phone but he hopes that it is not &#8220;needed.&#8221;
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41736208/gm-crosses-300k-ev-deliveries-in-us-since-2016-but-its-still-over-40-lower-than-teslas-sales-in-the" target="_blank" rel="noreferrer noopener">GM Crosses 300K EV Deliveries In US Since 2016, But It's Still Over 40% Lower Than Tesla's Sales In The First 9 Months Of 2024</a></li>
</ul>
Photo courtesy: Shutterstock

TSLA

Elon Musk Rejects Rumors Of A Tesla Phone, But Says The EV Giant Will Have To Make One If This Happens

<a href="https://www.nytimes.com/2024/11/05/us/politics/dixville-notch-election-vote-results.html">https://www.nytimes.com/2024/11/05/us/politics/dixville-notch-election-vote-results.html</a>
&nbsp;

Election Day Begins With Dixville Notch Midnight Vote - It's a Harris-Trump Tie In 6 Vote Tally

ProFrac Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACDC#NASDAQ">ACDC</a>) reported quarterly sales of $575.300 million which beat the analyst consensus estimate of $560.713 million by 2.60 percent. This is a 0.19 percent increase over sales of $574.200 million the same period last year.

ProFrac Holding Q3 Sales $575.300M Beat $560.713M Estimate, Net loss $43.5M Compared To Net Loss Of $17.9M YoY

Macro Economic Events

Econ #s

Economics

U.K. Composite Purchasing Managers' Index For October 51.8 Vs. 51.7 Est.; 52.6 Prior

U.K. Services Purchasing Managers Index For October 52.0 Vs. 51.8 Est.; 52.4 Prior

Wedbush analyst Yun Zhong assumes MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Outperform rating and lowers Price Target of $73.

Price Target

Initiation

Analyst Ratings

MLTX

Wedbush Assumes MoonLake at Outperform, Lowers Price Target of $73

Wedbush analyst Yun Zhong initiates coverage on Rezolute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLT#NASDAQ">RZLT</a>) with a Outperform rating and announces Price Target of $12.

RZLT

Wedbush Initiates Coverage On Rezolute with Outperform Rating, Announces Price Target of $12

Wedbush analyst Yun Zhong initiates coverage on Protagonist Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>) with a Outperform rating and announces Price Target of $58.

PTGX

Wedbush Initiates Coverage On Protagonist Therapeutics with Outperform Rating, Announces Price Target of $58

In a recent study, the National Retail Federation (NRF) warns that Donald Trump&#8217;s proposed tariffs could significantly impact American consumers, potentially reducing annual spending by $78 billion.
What Happened: The NRF study highlights the potential consequences of Trump&#8217;s tariff proposal on consumer goods, particularly those imported from China. The report, released on Monday, suggests that the tariffs could lead to increased prices on essential items such as apparel, toys, and appliances, affecting consumer spending habits, Reuters reported.
Jonathan Gold, NRF&#8217;s vice president of supply chain and customs policy, emphasized the reliance of retailers on imports to offer a diverse range of affordable products. The proposed tariffs, which include a 10% universal tariff on all imports and a possible 60% to 100% tariff on Chinese imports, could disproportionately impact low-income families as costs are passed on to consumers.
See Also: <a href="https://www.benzinga.com/news/24/11/41701311/scaramucci-says-trump-should-be-taken-into-custody-over-alleged-threat-against-liz-cheney?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Scaramucci Says Trump &#8216;Should Be Taken Into Custody&#8217; Over Alleged Threat Against Liz Cheney</a>
The NRF also projects a modest growth in holiday sales, expecting an increase of up to 3.5% to $989 billion, marking the slowest growth in six years.
Why It Matters: The proposed tariffs have sparked significant controversy, with a <a href="https://www.benzinga.com/startups/24/10/41561517/trump-pushes-forward-with-controversial-tariff-plan-despite-growing-backlash-from-voters-who-strongl">growing backlash from voters</a> who oppose the plan. An NBC News poll revealed that 44% of voters are less likely to support a candidate advocating for universal tariffs, highlighting the divisive nature of the issue amid economic challenges like inflation and fragile supply chains.
Furthermore, global concerns have been raised about the <a href="https://www.benzinga.com/markets/equities/24/10/41592365/trump-tariffs-will-be-negative-not-just-for-emerging-markets-but-across-the-world-says-singapore">potential negative impact</a> of Trump&#8217;s tariffs. Singapore&#8217;s state-owned investment firm, Temasek, warned that a Trump re-election could slow global growth, affecting U.S. companies and financial markets. The firm expressed concerns about increased uncertainty due to tariffs, which could lead to a stronger dollar and higher rates.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/11/41732623/bakery-that-often-predicts-election-outcomes-has-this-candidate-winning-in-trump-harris-battle-d?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bakery That Often Predicts Election Outcomes Has This Candidate Winning In Trump, Harris Battle: &#8216;Doughmacracy For All!&#8217;</a></li>
</ul>
Image via Flickr
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Trump Tariff Proposed May Cost Americans $78B In Spending: Study

Zoomcar Holdings, Inc. ("Zoomcar" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>), the Nasdaq-listed leading marketplace for self-drive car sharing, announced a major expansion in its customer support efforts, doubling its customer support team to ensure faster, more efficient assistance for both Hosts and Guests on its platform. This expansion marks a significant step in addressing customer feedback and improving overall service quality.
&nbsp;
In a key initiative, Zoomcar has also launched a dedicated team called Host Success Team, to assist new Hosts in onboarding their vehicles and optimising earnings. This specialised team guides Hosts through every stage of their journey on the platform, providing continuous support to help them thrive.
In addition to expanding the team, Zoomcar has moved to a multi-channel support model. This now includes inbound and outbound calls, chatbot based ticketing support and a <a href="https://press.zoomcar.com/in/zoomcar-pioneers-ai-innovation-unveils-beta-ai-assistant-to-enhance-host-and-guest-experience/">Generative AI (Gen AI) Assistant</a>&nbsp;that offers 24x7 assistance. This enhanced customer support framework has already led to an 50% reduction in in-app escalations, with continued improvements expected as the new measures take full effect.

ZCAR

Zoomcar Expands Customer Support, Doubles Team for Faster Service

Lilium N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILM#NASDAQ">LILM</a>), a leading electric aircraft manufacturer and pioneer in Regional Air Mobility (RAM), announces that it has appointed KPMG to conduct an open, transparent and fair M&amp;A process. First investor briefings will start soon.
This followed the local court of Weilheim's approval of the insolvency filing of Lilium's German subsidiaries and the court's granting of Lilium's application for self-administration.
Preliminary insolvency proceedings under self-administration are court-ordered restructuring proceedings aimed at preserving the business. The management remains in charge and leads the business through the proceedings, supported by restructuring experts.
The court has appointed to the German subsidiaries' Boards of Management with immediate effect two restructuring-experienced lawyers, Prof. Dr. Gerrit Hölzle and Dr. Thorsten Bieg as Chief Insolvency Officers (CIOs). Both have already successfully advised a large number of companies in crisis situations. Most recently, they worked for Senvion and The Social Chain AG, among others. They will now oversee the reorganization of Lilium's German subsidiaries.
The Local Court of Weilheim has also appointed attorney Mr. Ivo-Meinert Willrodt, Managing Partner at PLUTA Rechtsanwalts GmbH, as the provisional custodian. The restructuring expert is an attorney and specialist lawyer for insolvency and restructuring law and has already acted as trustee for the solar car start-up Sono Motors and the drone manufacturer EMT, among others. His role is to protect the interests of the creditors in the proceedings.

LILM

Lilium Taps KPMG for M&A as German Subsidiaries Enter Insolvency

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on NTLA stock, giving a Buy rating today. Mani Foroohar has given his Bu...

Intellia Therapeutics: Promising Phase 2 Results and Growth Potential Justify Buy Rating

Citi analyst David Lebowitz lowered the firm's price target on Intellia Therapeutics (NTLA) to $19 from $25 and keeps a Neutral rating on the share...

Intellia Therapeutics price target lowered to $19 from $25 at Citi

David Lebowitz, an analyst from Citi, maintained the Hold rating on Intellia Therapeutics (NTLA – Research Report). The associated price target is ...

Intellia Therapeutics' NTLA-2002: Hold Rating Amid Competitive Challenges and Safety Concerns

Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity

Intellia Therapeutics ( ($NTLA) ) has provided an announcement. Intellia Therapeutics has announced promising Phase 2 results for NTLA-2002, a CRIS...

Intellia Therapeutics Advances with Promising Phase 2 Results

Tracking Cathie Wood's ARK Invest 13F Portfolio - Q3 2024 Update

Warning: NTLA is at high risk of performing badly

JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on NTLA stock, giving a Buy rating on October 25. Debanjana Chatterje...

Intellia Therapeutics: Positive Outlook and Buy Rating Amid Promising Data for ATTR-CM Treatment

Data Underwhelms - Intellia's Cash, Data And Competition Are A Challenging Story

ALNY

ARKB

ARKF

ARKG

ARKK

ARKQ

ARKW

ARKX

BCRX

BEAM

COIN

CRSP

DKNG

HOOD

IONS

NTLA

PATH

RBLX

REGN

ROKU

RXRX

SHOP

TKPHF

Press Releases

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates

Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting

Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions

Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Comments

Intellia Therapeutics

Actualités

Dernières nouvelles pour Intellia Therapeutics (NASDAQ:NTLA) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL